Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants

INTRODUCTION: Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examine utilization within insured populations as a whole. This study describes out...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavilack, Melissa, Clifford, Robert A., Gonzales, Tara, Kong, Amanda M., Wade, Sally, McLaurin, Kimmie K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840097/
https://www.ncbi.nlm.nih.gov/pubmed/29149439
http://dx.doi.org/10.1007/s40121-017-0178-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840097/
https://www.ncbi.nlm.nih.gov/pubmed/29149439
http://dx.doi.org/10.1007/s40121-017-0178-6

Ejemplares similares